Nevirapine (NVP) is used in developing countries as first-line treatment of HIV infection. Unfortunately, its use is associated with common serious adverse drug reactions, such as liver toxicity and the most severe and rare Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). GSTT1 and GSTM1 genes code for enzymes involved in the metabolism of a wide range of drugs. We hypothesized that this gene variability could be implicated in NVP adverse reactions.
Ciccacci, C., Latini, A., Politi, C., Mancinelli, S., Marazzi, M.c., Novelli, G., et al. (2017). Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 73(10), 1253-1259 [10.1007/s00228-017-2295-2].
Impact of glutathione transferases genes polymorphisms in nevirapine adverse reactions: a possible role for GSTM1 in SJS/TEN susceptibility
Ciccacci C.;Mancinelli S.;Novelli G.;Palombi L.;Borgiani P.
2017-01-01
Abstract
Nevirapine (NVP) is used in developing countries as first-line treatment of HIV infection. Unfortunately, its use is associated with common serious adverse drug reactions, such as liver toxicity and the most severe and rare Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). GSTT1 and GSTM1 genes code for enzymes involved in the metabolism of a wide range of drugs. We hypothesized that this gene variability could be implicated in NVP adverse reactions.| File | Dimensione | Formato | |
|---|---|---|---|
|
GST and SJS.pdf
solo utenti autorizzati
Licenza:
Copyright dell'editore
Dimensione
444.3 kB
Formato
Adobe PDF
|
444.3 kB | Adobe PDF | Visualizza/Apri Richiedi una copia |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
